News 2020-04-21
Porton Successfully Receives Third US FDA Inspection.
We are proud to announce that Porton’s cGMP-compliant Erlang site located in the Chonqing Metro Region, China passed a 4-day general inspection [April 24-28, 2016] by the US FDA without any Form 483 observations. This is the third successful inspection of our China sites by the US FDA since 2013. Supported by a unified Quality Management System and Corporate Quality Group, Porton’s production sites continue to reliably deliver efficient and high-quality manufacturing solutions across the full life cycle for our valued global customers. Learn how we can help you – contact us today!
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Others
More
News 2025-10-20
Porton Warmly Congratulates Partner XZenith on Its Listing on the Main Board of the Hong Kong Stock Exchange
Porton congratulates XZenith on its HK listing, highlighting our CDMO partnership for innovative drug development and commercialization.
News 2025-10-10
Porton Newsletter - September 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities Others
